Description: Bioqual, Inc. is a provider of research, development, consulting and testing/assay services to commercial clients and Government laboratories. The Company supports the National Institutes of Health by providing research services in the research areas of cancer, acquired immune deficiency syndrome (AIDS), hepatitis, influenza, immunology, transgenics, contraception, breeding and development of genetically defined animals, and neurobiology and behavior. The Company's research contracts consist of cancer virus studies, congenic animal development and monoclonal antibody research. The Company's research services include primate biology and medicine, small laboratory animal sciences, infectious disease research, in vitro laboratory services, environmental enrichment and behavior, good laboratory practice (GLP) studies, and partnerships for contracts and grants. The Company holds government contracts, which utilize the non-human primate model to study assorted human diseases.
Home Page: www.bioqual.com
9600 Medical Center Drive
Rockville,
MD
20850-3336
United States
Phone:
240 404 7654
Officers
| Name | Title |
|---|---|
| Dr. Marisa St. Claire DVM | VP - Primate Biology and Medicine |
| Dr. Mark G. Lewis Ph.D. | Chairman, CEO & Pres |
| Mr. Charles C. Kirk Jr., CPA | Chief Financial Officer |
| Mitch Franklin | Chief Operating Officer |
| Ms. Hanne Andersen-Elyard Ph.D. | Initial Chief Scientific Officer |
| Nancy A. Madden | VP of Admin. Operations & Biosafety Officer |
| Dr. J. Thomas August M.D. | Consultant & Scientific Adviser |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 13.3116 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0.9568 |
| IPO Date: | |
| Fiscal Year End: | May |
| Full Time Employees: | 0 |